Equities

Calidi Biotherapeutics Inc

Calidi Biotherapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.01
  • Today's Change-0.07 / -6.48%
  • Shares traded46.74k
  • 1 Year change-96.61%
  • Beta--
Data delayed at least 15 minutes, as of Oct 09 2024 21:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's novel stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Its clinical-stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses. Its preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach shall potentially treat, or even prevent, metastatic disease. Its product candidates include CLD-101 for Recurrent HGG; CLD-201 for Advanced Solid Tumors, and CLD-400 (RTNova) for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline product candidates, the Company's is also engaged in discovery research of CLD-301 (AAA) for multiple Indications.

  • Revenue in USD (TTM)0.00
  • Net income in USD-24.92m
  • Incorporated2021
  • Employees41.00
  • Location
    Calidi Biotherapeutics Inc4475 Executive Drive, Suite 200SAN DIEGO 92121United StatesUSA
  • Phone+1 (858) 794-9600
  • Fax+1 (858) 794-9605
  • Websitehttps://www.calidibio.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Mustang Bio Inc0.00-32.06m7.90m80.00---------2.91-2.910.00-0.23840.00----0.00-170.53-70.02-727.24-79.98--------------------33.44---60.75--
Plus Therapeutics Inc (USA)5.51m-13.23m7.96m20.00------1.44-3.05-3.051.19-1.340.4336----275,450.00-104.14-59.18---133.04-----240.15-470.45---4.17----2,093.30-5.8934.32--3.77--
Vitro Biopharma Inc1.85m-9.72m8.05m10.00------4.35-2.18-2.180.4159-1.640.23241.5824.96185,140.00-122.00---1,146.77--82.88---524.87--0.169-5.375.49---46.45--31.01------
Enzon Pharmaceuticals Inc26.00k314.00k8.17m0.0026.032.69--314.270.00420.00420.00040.62770.0006------3.39-0.86543.42-0.8851----6,111.54-159.43----0.00---100.00--106.71-55.86----
Nascent Biotech Inc0.00-1.92m8.30m-----------0.012-0.0120.00-0.0030.00-------1,256.81-708.50-----------589.83------------25.47------
Transcode Therapeutics Inc0.00-17.91m8.33m10.00--2.65-----75.48-75.480.000.1820.00----0.00-334.48-133.14-973.00-181.26-----------90.110.00-------5.59------
Check Cap Ltd0.00-17.57m8.48m85.00--0.3581-----3.00-3.000.004.050.00-------49.87-54.23-53.46-60.24------------0.00------8.06---2.46--
Calidi Biotherapeutics Inc0.00-24.92m8.73m41.00---------5.41-5.410.00-1.820.00----0.00-279.89-----------------27.58-----100.00---14.90------
Traws Pharma Inc226.00k-137.05m8.77m16.00------38.80-138.17-138.170.25576.030.0092--12.9114,125.00-557.63-63.43-896.39-85.72-----60,641.15-3,257.92----0.00--0.00-28.720.0844------
Inhibikase Therapeutics Inc79.57k-18.38m8.88m8.00--1.68--111.63-2.93-2.930.01260.70630.0051----9,946.25-117.93-66.49-148.63-85.55-----23,102.16-1,139.14----0.00--111.03-42.21-5.40------
Soligenix Inc494.62k-7.04m9.21m13.00--1.80--18.63-9.58-9.580.61522.250.0418--8.7038,047.69-59.45-75.40-121.64-154.328.7522.83-1,423.81-620.02----0.4421---11.54-30.6755.50------
Viracta Therapeutics Inc0.00-45.34m9.27m40.00---------1.16-1.160.000.06780.00----0.00-83.82-86.35-140.98-106.38-------11,853.94---59.780.8753-------3.78------
BioCardia Inc428.00k-8.56m9.28m16.00------21.68-5.40-5.400.2636-0.92330.0923--6.8526,750.00-184.48-107.34-1,075.25-154.17-----1,999.77-1,779.24---------64.72-5.262.82---28.89--
Galecto Inc0.00-25.43m9.35m13.00--0.3445-----23.45-23.450.0021.740.00----0.00-59.06-48.46-75.34-52.36------------0.00------37.77------
Molecular Templates Inc25.47m-15.63m9.36m62.00--1.32--0.3674-2.70-2.704.241.080.8189--47.65410,806.40-50.24-51.78-113.26-73.14-----61.35-228.33----0.00--190.1033.9691.24---48.87--
Data as of Oct 09 2024. Currency figures normalised to Calidi Biotherapeutics Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.